

For Immediate Release:

March 10, 2010

Contact:

Mary Kuramoto

513-579-9911 x 2523

m.kuramoto@medpace.com**Medpace Executive Director David G. Orloff, MD, to co-chair Educational Satellite Symposia, New Frontiers in Anti-Atherosclerotic Therapies**

CINCINNATI, OH, March 10, 2010 - Medpace, Inc., a leading global full-service clinical research organization today announced that Dr. David G. Orloff, Executive Director, Regulatory Affairs, will co-chair *New Frontiers in Anti-Atherosclerotic Therapies*, a satellite symposium to be held in tandem at the 59th Annual Scientific Session of the American College of Cardiology in Atlanta on Saturday, March 13 from 7:00 am – 12:00 pm. This course will review new therapeutic targets for atherosclerotic cardiovascular disease. Sponsored by the Cleveland Clinic Foundation Center for Continuing Education, this series of symposia is designed to review novel therapeutic strategies in dealing with this disease. Medpace therapeutic expert, David Orloff, MD, is a regular presenter and commentator on current FDA Guidance on cardiovascular risk assessment on an international level.

Dr. Orloff is the Medpace Executive Director of Regulatory Affairs. He is the immediate past director of the Division of Metabolism and Endocrinology Products within the Center for Drug Evaluation and Research (CDER) of the FDA. Dr. Orloff is an endocrinologist and has 12 years of regulatory experience with major foci in diabetes, obesity, and lipid metabolism. He has research experience in molecular and cellular biology and clinical endocrinology at the National Institute of Child Health and Human Development (NICHD) and the National Institute of Diabetes, Digestive, and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH). He was a consultant to the National Cholesterol Education Program, Adult Treatment Plan III, and is an advisor to multiple pharmaceutical companies working in the metabolism and diabetes fields.

For more information on this session, visit www.ccfme.org/Frontier10.

###

ABOUT MEDPACE

Medpace is a leading global full-service clinical research organization providing Phase I-IV core development services for drug, biologic, and device programs. With medical and regulatory expertise in multiple therapeutic specialties, Medpace has assembled the industry's most experienced and therapeutically focused teams to execute at every level of the company's operations, providing complete and seamless drug development services. In June 2009 Medpace was rated as the best CRO by U.S. Investigators in the 2009, CenterWatch Site Survey.

Medpace creates strategic partnerships with pharmaceutical and biotechnology companies to provide the most efficient and cost-effective path to drug development – from program planning and execution to product approval.

With more than 1,000 employees and clinical trial experience in over 40 countries, Medpace has the global reach and capability to conduct studies and navigate regulatory requirements worldwide. In addition to Phase II-IV development services, Medpace provides Phase I / IIA clinical services from Medpace Clinical Pharmacology, central laboratory and therapeutically specialized testing from Medpace Reference Laboratories, complete bioanalytical services in all stages of drug development from Medpace Bioanalytical Laboratories, and centralized imaging core laboratory management and reading from Imagepace.

Visit the Medpace website at www.medpace.com